377 related articles for article (PubMed ID: 16750259)
1. Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors.
Garuti G; Cellani F; Centinaio G; Montanari G; Nalli G; Luerti M
Gynecol Oncol; 2006 Nov; 103(2):599-603. PubMed ID: 16750259
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer.
Garuti G; Grossi F; Centinaio G; Sita G; Nalli G; Luerti M
Eur J Obstet Gynecol Reprod Biol; 2007 May; 132(1):101-6. PubMed ID: 16678960
[TBL] [Abstract][Full Text] [Related]
3. Baseline endometrial assessment before tamoxifen for breast cancer in asymptomatic menopausal women.
Garuti G; Cellani F; Centinaio G; Sita G; Nalli G; Luerti M
Gynecol Oncol; 2005 Jul; 98(1):63-7. PubMed ID: 15894357
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic behavior of endometrial hyperplasia during tamoxifen therapy for breast cancer.
Garuti G; Cellani F; Centinaio G; Sita G; Nalli G; Luerti M
Gynecol Oncol; 2006 May; 101(2):269-73. PubMed ID: 16297970
[TBL] [Abstract][Full Text] [Related]
5. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
6. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound.
Gerber B; Krause A; Müller H; Reimer T; Külz T; Makovitzky J; Kundt G; Friese K
J Clin Oncol; 2000 Oct; 18(20):3464-70. PubMed ID: 11032586
[TBL] [Abstract][Full Text] [Related]
7. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
8. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Coibion M; Bianco AR;
Hum Reprod; 2005 Jan; 20(1):294-301. PubMed ID: 15513977
[TBL] [Abstract][Full Text] [Related]
9. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
10. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: an ultrasound, color flow Doppler, hysteroscopic and histological study.
Exacoustos C; Zupi E; Cangi B; Chiaretti M; Arduini D; Romanini C
Ultrasound Obstet Gynecol; 1995 Dec; 6(6):435-42. PubMed ID: 8903921
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait.
Al-Azemi M; Labib NS; Motawy MM; Temmim L; Moussa MA; Omu AE
Med Princ Pract; 2004; 13(1):30-4. PubMed ID: 14657616
[TBL] [Abstract][Full Text] [Related]
12. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
[TBL] [Abstract][Full Text] [Related]
13. Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2007 Jan; 101(2):185-90. PubMed ID: 16897434
[TBL] [Abstract][Full Text] [Related]
14. [Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy].
d'Arailh AS; Michy T; Pioud R; Dravet F; Classe JM
Gynecol Obstet Fertil; 2007 Dec; 35(12):1215-9. PubMed ID: 18035581
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
Lee M; Piao J; Jeon MJ
Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
[TBL] [Abstract][Full Text] [Related]
16. Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy.
Kieback DG; Harbeck N; Bauer W; Hadji P; Weyer G; Menschik T; Hasenburg A
Gynecol Oncol; 2010 Dec; 119(3):500-5. PubMed ID: 20832103
[TBL] [Abstract][Full Text] [Related]
17. The role of endovaginal ultrasonography and the value of endometrial biopsy in breast cancer patients on tamoxifen therapy.
Sivalingam N; Pathmalingam A
Singapore Med J; 1999 Jun; 40(6):402-4. PubMed ID: 10489508
[TBL] [Abstract][Full Text] [Related]
18. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
[TBL] [Abstract][Full Text] [Related]
19. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring.
Vosse M; Renard F; Coibion M; Neven P; Nogaret JM; Hertens D
Eur J Obstet Gynecol Reprod Biol; 2002 Feb; 101(1):58-63. PubMed ID: 11803101
[TBL] [Abstract][Full Text] [Related]
20. Continuous tamoxifen treatment in asymptomatic, postmenopausal breast cancer patients does not cause aggravation of endometrial pathologies.
Cohen I; Tepper R; Rosen DJ; Shapira J; Cordoba M; Dror Y; Altaras M; Beyth Y
Gynecol Oncol; 1994 Oct; 55(1):138-43. PubMed ID: 7959255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
